About cco

Manuscript Submission


Contact us

Focused Issues more

Figure left:Minesh Mehta,Department of Radiation Oncology, Miami Cancer Institute, Miami, FL, USA

Guest editor: Dr. Minesh Mehta (Figure left) - Minesh Mehta, M.B.Ch.B., received his medical degree from the University of Zambia in 1981 and proceeded to complete residency training in Radiation Oncology at the University of Wisconsin in 1988, following which he was appointed to the faculty of the University of Wisconsin's School of Medicine in the Department of Human Oncology. In 1997, he was appointed as the Chairman of the Department of Human Oncology, which he led for the subsequent 10 years. Additionally, he has successfully led the RTOG/NRG Brain Tumor Program for over 15 years, with continuous grant refunding. From 2010-12, Dr. Mehta was Professor of Radiation Oncology at Northwestern University where he was also co-leader of the Lurie Cancer Center's Solid Tumor Investigational Program. Dr. Mehta served as the founding medical director of the Maryland Proton Treatment Center in Baltimore from 2012-16, the area’s first proton treatment center. Currently, he leads Baptist Health South Florida as the Deputy Director of the Miami Cancer Institute, and Chief of Radiation Oncology, overseeing South Florida’s first Proton Therapy Center. 

Dr. Mehta's clinical activities have revolved around thoracic and central nervous system tumors where he has gained international recognition and acclaim, based on his clinical and academic productivity, which includes several hundred manuscripts, abstracts, book chapters, and speaker invitations. He has developed robust clinical research programs with an eye toward generating level I practice-changing evidence. His research has also included several innovations in areas including radiosensitizers, radioprotectors, as well as radiation oncology technology, including intensity modulated, image-guided radiation therapy, and proton therapy. Dr. Mehta has had several leadership responsibilities, including Departmental Chairmanship, residency program directorship, medical school course directorship, leadership in several national organizations such as ABS, ASCO, ASTRO, CCG, FDA, ISRS, SNO, etc. 

Figure right:Dr. Arpit Chhabra,Department of Radiation Oncology, The University of Maryland School of Medicine, Baltimore, Maryland, USA

Guest editor:Dr. Arpit Chhabra  (Figure right) - Arpit Chhabra MD, is a Post-Graduate Year-5 Radiation Oncology Senior Resident at the University of Maryland Medical Center. He completed his medical school training at New York University School of Medicine, and initiated his radiation oncology training at State University of New York-Downstate. His academic interests include gaining an in-depth understanding of clinical proton radiotherapy, with current involvement in multiple proton therapy research projects. 

Vol 5, No 4 (August 2016): Proton Therapy-Guest Editors: Minesh Mehta, Arpit Chhabra More >>
Vol 5, No 3 (June 2016): Multidisciplinary Management of Breast Cancer-Guest Editors: Charles M.... More >>
Vol 5, No 2 (April 2016): Nasopharyngeal Carcinoma-Guest Editors: Joseph Wee, Yoke-Lim Soong,... More >>

Charles M. Balch: Surgical Oncology Column more

Clinical trials in lung cancer surgery and research cooperation: With China having an... More >>
Training and certification of the surgical oncologist: Surgical Oncology has evolved as a... More >>


An overview of modern proton therapy
Arpit Chhabra, Katja Langen, Minesh P. Mehta

Review Article

Treatment of common pediatric CNS malignancies with proton therapy
Arpit Chhabra, Anita Mahajan
Proton therapy for the management of uveal melanoma and other ocular tumors
Kavita K. Mishra, Inder K. Daftari
Proton therapy for tumors of the base of the skull
Georges Noel, Vinai Gondi
Novel applications of proton therapy in breast carcinoma
John J. Cuaron, Shannon M. MacDonald, Oren Cahlon
Proton beam therapy for the treatment of esophageal cancer
Steven H. Lin, Christopher L. Hallemeier, Michael Chuong
Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer
Matthew R. McKeever, Terence T. Sio, G. Brandon Gunn, Emma B. Holliday, Pierre Blanchard, Merrill S. Kies, Randal S. Weber, Steven J. Frank
Controversies in proton therapy for prostate cancer
Curtis Bryant, Randal H. Henderson, Bradford S. Hoppe, William M. Mendenhall, R. Charles Nichols, Zhong Su, Zuofeng Li, Nancy P. Mendenhall
Cost-comparativeness of proton versus photon therapy
Vivek Verma, Chirag Shah, Jean-Claude M. Rwigema, Timothy Solberg, Xiaofeng Zhu, Charles B. Simone II


Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Jun Guo, Shukui Qin, Jun Liang, Tongyu Lin, Lu Si, Xiaohong Chen, Zhihong Chi, Chuanliang Cui, Nan Du, Yun Fan, Kangsheng Gu, Fang Li, Junling Li, Yongheng Li, Houjie Liang, Jiwei Liu, Man Lu, Aiping Lu, Kejun Nan, Xiaohui Niu, Hongming Pan, Guoxin Ren, Xiubao Ren, Yongqian Shu, Xin Song, Min Tao, Baocheng Wang, Wenbin Wei, Di Wu, Lingying Wu, Aiwen Wu, Xiaolin Xu, Junyi Zhang, Xiaoshi Zhang, Yiping Zhang, Huiyan Zhu, written on behalf of Chinese Society of Clinical Oncology (CSCO) Melanoma Panel


Training a new generation of surgeons worldwide who are also oncologists
Charles M. Balch, Graeme J. Poston, Daniel Coit, Riccardo Audisio


Can EGFR mutation status evolve with chemotherapy?
Eric S. Kim, David J. Stewart, Alok A. Khorana

Review Article

The spectrum of clinical trials aiming at personalizing medicine
Christophe Le Tourneau, Maud Kamal, Marie Alt, Loic Verlingue, Vincent Servois, Marie-Paule Sablin, Nicolas Servant, Xavier Paoletti
Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine
Sumithra J. Mandrekar, Daniel J. Sargent
From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer
Sophie Doisneau-Sixou, Nadia Harbeck
Melanoma adjuvant therapy
Prashanth M. Thalanayar, Sanjiv S. Agarwala, Ahmad A. Tarhini
Genotyping of cutaneous melanoma
Isabella C. Glitza, Michael A. Davies
Treatment of KIT-mutated metastatic mucosal melanoma
Kevin B. Kim, Anas Alrwas
New approaches in primary central nervous system lymphoma
Eleanor Fraser, Katherine Gruenberg, James L. Rubenstein
Molecular and clinical implementations of ovarian cancer mouse avatar models
Amira A. Zayed, Sumithra J. Mandrekar, Paul Haluska
An overview of the design and conduct of the BATTLE trials
Suyu Liu, J. Jack Lee
Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials
Ryan S. Alden, Sumithra J. Mandrekar, Geoffrey R. Oxnard
Risk- and response-adapted strategies for the management of Hodgkin lymphoma
Marcus Remer, Peter W. M. Johnson
Prognostic scores for brain metastasis patients: use in clinical practice and trial design
Vyshak Alva Venur, Manmeet S. Ahluwalia
Strategies for preservation of memory function in patients with brain metastases
Nicholas B. Dye, Vinai Gondi, Minesh P. Mehta
Management of neoplastic meningitis
Patrick Roth, Michael Weller
Design and statistical principles of the SHIVA trial
Xavier Paoletti, Bernard Asselain, Maud Kamal, Nicolas Servant, Philippe Huppé, Ivan Bieche, Christophe Le Tourneau
Autologous tracheal replacement for cancer
Dominique Fabre, Elie Fadel, Sacha Mussot, Frederic Kolb, Nicolas Leymarie, Olaf Mercier, Thierry Le Chevalier, Philippe G. Dartevelle
The staging value of sentinel lymph node biopsy for breast cancer: translating pathologic findings to clinical practice
Jean Bao, Cory Donovan, Alice Chung, Armando E. Giuliano
HER2-positive breast cancer, how far away from the cure?—on the current situation of anti-HER2 therapy in breast cancer treatment and survival of patients
Ning Liao
Training of breast surgical oncologists
Mediget Teshome, Henry M. Kuerer
The way to precision medicine of our team
Fengrui Xu, Xiaodi Wang, Zefei Jiang
Genetic testing for hereditary breast cancer in Asia—moving forward
Ava Kwong

Original Article

Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments
Laura E. Johnson, Jordan T. Becker, Jason A. Dubovsky, Brian M. Olson, Douglas G. McNeel

Review Articles

Prevention of colorectal cancer and dietary management
Ningqi Hou, Dezheng Huo, James J. Dignam
Stage II colon cancer
David N. Church, Rachel Midgley, David J. Kerr
Mining the ACCENT database: a review and update
Lindsay A. Renfro, Qian Shi, Daniel J. Sargent
Status of hepatocellular carcinoma in South Korea
Seung Kew Yoon, Hoo Geun Chun

Statistics in Oncology Clinical Trials

Adaptive randomized phase II design for biomarker threshold selection and independent evaluation
Lindsay A. Renfro, Christina M. Coughlin, Axel M. Grothey, Daniel J. Sargent
Adaptive clinical trial designs in oncology
Yong Zang, J. Jack Lee
Statistical aspect of translational and correlative studies in clinical trials
Herbert Pang, Xiaofei Wang

Updates on Surgical Oncology

Clinical trials in lung cancer surgery and research cooperation
Wen-Zhao Zhong, Hao-Ran Zhai, Yi-Long Wu

Below are the latest Chinese Clinical Oncology articles published online ahead of print publication.